Literature DB >> 19054502

Opposite effects of catechol-O-methyltransferase Val158Met on cortical function in healthy subjects and patients with schizophrenia.

Diana P Prata1, Andrea Mechelli, Cynthia H Y Fu, Marco Picchioni, Fergus Kane, Sridevi Kalidindi, Colm McDonald, Oliver Howes, Eugenia Kravariti, Arsime Demjaha, Timothea Toulopoulou, Marta Diforti, Robin M Murray, David A Collier, Philip K McGuire.   

Abstract

BACKGROUND: Catechol-O-methyltransferase (COMT) is essential for dopamine metabolism in the brain, and normal variation in the COMT Val158Met polymorphism can influence regional brain function during cognitive tasks. How this is affected when central dopamine function is perturbed is unclear. We addressed this by comparing the effects of COMT Val158Met genotype on cortical activation during a task of executive functions in healthy and schizophrenic subjects.
METHODS: We studied 90 subjects comprising 48 healthy volunteers (15 Met158/Met158, 20 Val158/Met158, and 13 Val158/Val158) and 42 patients with DSM-IV schizophrenia (13 Met158/Met158, 17 Val158/Met158, and 12 Val158/Val158). Subjects were studied with functional magnetic resonance imaging while performing a verbal fluency task, with performance recorded online. Main effects of genotype and diagnosis and their interaction on cortical activation and functional connectivity were assessed using SPM5.
RESULTS: In the right peri-Sylvian cortex, the Met158 allele of the COMT Val158Met polymorphism was associated with greater activation than the Val158 allele in control subjects; the converse applied in patients (Z = 4.3; false discovery rate p = .04). There was also a strong trend for a group x genotype interaction on functional connectivity between this right peri-Sylvian region and the left anterior insula/operculum (Z = 3.4; p < .001, uncorrected). These findings were independent of between-group differences in task performance, medication, demographic factors, or IQ.
CONCLUSIONS: Frontotemporal function during verbal generation is modulated by variation in COMT genotype. This effect is altered in schizophrenia, which may reflect the perturbation of central dopamine function associated with the disorder.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19054502     DOI: 10.1016/j.biopsych.2008.09.027

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  26 in total

1.  ZNF804A and cortical structure in schizophrenia: in vivo and postmortem studies.

Authors:  Carl Christoph Schultz; Igor Nenadic; Brien Riley; Vladimir I Vladimirov; Gerd Wagner; Kathrin Koch; Claudia Schachtzabel; Thomas W Mühleisen; Buket Basmanav; Markus M Nöthen; Thomas Deufel; Michael Kiehntopf; Marcella Rietschel; Jürgen R Reichenbach; Sven Cichon; Ralf G M Schlösser; Heinrich Sauer
Journal:  Schizophr Bull       Date:  2013-09-27       Impact factor: 9.306

2.  Morphological changes in gray matter volume correlate with catechol-O-methyl transferase gene Val158Met polymorphism in first-episode treatment-naïve patients with schizophrenia.

Authors:  Ming-Li Li; Bo Xiang; Yin-Fei Li; Xun Hu; Qiang Wang; Wan-Jun Guo; Wei Lei; Chao-Hua Huang; Lian-Sheng Zhao; Na Li; Hong-Yan Ren; Hui-Yao Wang; Xiao-Hong Ma; Wei Deng; Tao Li
Journal:  Neurosci Bull       Date:  2015-01-06       Impact factor: 5.203

Review 3.  COMT, neuropsychological function and brain structure in schizophrenia: a systematic review and neurobiological interpretation.

Authors:  Elisa Ira; Martina Zanoni; Mirella Ruggeri; Paola Dazzan; Sarah Tosato
Journal:  J Psychiatry Neurosci       Date:  2013-11       Impact factor: 6.186

4.  Antipsychotics reverse abnormal EEG complexity in drug-naive schizophrenia: a multiscale entropy analysis.

Authors:  Tetsuya Takahashi; Raymond Y Cho; Tomoyuki Mizuno; Mitsuru Kikuchi; Tetsuhito Murata; Koichi Takahashi; Yuji Wada
Journal:  Neuroimage       Date:  2010-02-10       Impact factor: 6.556

5.  Catechol-o-methyl transferase (COMT) val158met polymorphism and adolescent cortical development in patients with childhood-onset schizophrenia, their non-psychotic siblings, and healthy controls.

Authors:  Armin Raznahan; Deanna Greenstein; Yohan Lee; Robert Long; Liv Clasen; Pete Gochman; Anjene Addington; Jay N Giedd; Judith L Rapoport; Nitin Gogtay
Journal:  Neuroimage       Date:  2011-05-15       Impact factor: 6.556

Review 6.  Intermediate phenotypes in psychiatric disorders.

Authors:  Roberta Rasetti; Daniel R Weinberger
Journal:  Curr Opin Genet Dev       Date:  2011-03-04       Impact factor: 5.578

7.  Epistasis between the DAT 3' UTR VNTR and the COMT Val158Met SNP on cortical function in healthy subjects and patients with schizophrenia.

Authors:  Diana P Prata; Andrea Mechelli; Cynthia H Y Fu; Marco Picchioni; Timothea Toulopoulou; Elvira Bramon; Muriel Walshe; Robin M Murray; David A Collier; Philip McGuire
Journal:  Proc Natl Acad Sci U S A       Date:  2009-07-28       Impact factor: 11.205

Review 8.  Cognitive control deficits in schizophrenia: mechanisms and meaning.

Authors:  Tyler A Lesh; Tara A Niendam; Michael J Minzenberg; Cameron S Carter
Journal:  Neuropsychopharmacology       Date:  2010-09-15       Impact factor: 7.853

9.  Functional variation of the dopamine D2 receptor gene is associated with emotional control as well as brain activity and connectivity during emotion processing in humans.

Authors:  Giuseppe Blasi; Luciana Lo Bianco; Paolo Taurisano; Barbara Gelao; Raffaella Romano; Leonardo Fazio; Apostolos Papazacharias; Annabella Di Giorgio; Grazia Caforio; Antonio Rampino; Rita Masellis; Audrey Papp; Gianluca Ursini; Lorenzo Sinibaldi; Teresa Popolizio; Wolfgang Sadee; Alessandro Bertolino
Journal:  J Neurosci       Date:  2009-11-25       Impact factor: 6.167

10.  Verbal fluency deficits and altered lateralization of language brain areas in individuals genetically predisposed to schizophrenia.

Authors:  Tejas S Bhojraj; Alan N Francis; Rajaprabhakaran Rajarethinam; Shaun Eack; Shreedhar Kulkarni; Konasale M Prasad; Debra M Montrose; Diana Dworakowski; Vaibhav Diwadkar; Matcheri S Keshavan
Journal:  Schizophr Res       Date:  2009-10-17       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.